Trending NewsTrending NewsNASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis $4.13 +0.24 (+6.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.09 -0.04 (-0.97%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MannKind Stock (NASDAQ:MNKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MannKind alerts:Sign Up Key Stats Today's Range$3.98▼$4.2350-Day Range$2.96▼$4.5252-Week Range$2.23▼$6.51Volume9.44 million shsAverage Volume4.67 million shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$8.97Consensus RatingModerate Buy Company Overview MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. Read More MannKind Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreMNKD MarketRank™: MannKind scored higher than 60% of companies evaluated by MarketBeat, and ranked 373rd out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingMannKind has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialMannKind has a consensus price target of $8.97, representing about 117.2% upside from its current price of $4.13.Amount of Analyst CoverageMannKind has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MannKind's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.06) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -58.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -58.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MannKind's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.37% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 5.85.Change versus previous monthShort interest in MannKind has recently increased by 7.65%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.77 News SentimentMannKind has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for MannKind this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows6 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,733.00 in company stock.Percentage Held by Insiders2.60% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNKD Stock News HeadlinesMNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism BuildsJuly 25 at 1:29 AM | finance.yahoo.comFDA approves Mannkind's at-home treatment option for heart failure or kidney diseaseJuly 25 at 1:29 AM | msn.comThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50. | Brownstone Research (Ad)MannKind Raises $50 Million in Private PlacementJuly 24 at 4:51 PM | tipranks.comMannKind shares rise on announcing $50M private placement financingJuly 24 at 3:27 PM | msn.comMannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload TranscriptJuly 24 at 3:27 PM | seekingalpha.comMannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with ...July 24 at 3:27 PM | markets.businessinsider.comFDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney DiseaseJuly 24 at 2:31 PM | benzinga.comSee More Headlines MNKD Stock Analysis - Frequently Asked Questions How have MNKD shares performed this year? MannKind's stock was trading at $5.67 at the beginning of 2026. Since then, MNKD stock has decreased by 27.2% and is now trading at $4.13. How were MannKind's earnings last quarter? MannKind Corporation (NASDAQ:MNKD) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.03. MannKind's revenue for the quarter was up 15.1% compared to the same quarter last year. Read the conference call transcript. Who are MannKind's major shareholders? Top institutional shareholders of MannKind include Prodigy Asset Management LLC (0.01%). Insiders that own company stock include Michael Castagna, Stuart A Tross, David Thomson, Steven B Binder and Sanjay R Singh. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings5/06/2026Today7/25/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MNKD's financial health is in the Green zone, according to TradeSmith. MNKD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees400Year Founded1991Price Target and Rating Average Price Target for MannKind$8.97 High Price Target$15.00 Low Price Target$4.75 Potential Upside/Downside+117.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.86 million Net Margins-6.63% Pretax Margin-7.92% Return on Equity-11.21% Return on Assets-3.92% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.50 Sales & Book Value Annual Sales$348.97 million Price / Sales3.66 Cash Flow$0.06 per share Price / Cash Flow66.74 Book Value($0.17) per share Price / Book-24.29Miscellaneous Outstanding Shares308,950,000Free Float300,917,000Market Cap$1.28 billion OptionableOptionable Beta1.09 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MNKD) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts